about
Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinomaScreening and diagnosis of HBV in low-income and middle-income countries.Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.Delivery of Tapasin-modified CTL epitope peptide via cytoplasmic transduction peptide induces CTLs by JAK/STAT signaling pathway in vivo.INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment.
P2860
Q28080175-7CC2F66E-743B-4C4C-9A1F-6422A982DB33Q38953790-70868E3B-9F30-44E4-9BE4-30E44B6B70A3Q40185369-EB74902F-2E8D-4D30-AFB6-6CBDA7970D45Q47552661-40B825C3-C7B5-475E-9346-36D31B38E37CQ54216584-2047ED8C-B286-4894-9C8E-7425BEEEF131Q54263472-D2A5154E-4075-4ACE-94E6-C9240CD6039DQ55517833-06DEBE46-5A28-4AD2-BCBF-1B43C60CFD04
P2860
description
2016 nî lūn-bûn
@nan
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
name
HBV: Do I treat my immunotolerant patients?
@en
type
label
HBV: Do I treat my immunotolerant patients?
@en
prefLabel
HBV: Do I treat my immunotolerant patients?
@en
P2860
P356
P1433
P1476
HBV: Do I treat my immunotolerant patients?
@en
P2093
Jiannis Vlachogiannakos
P2860
P356
10.1111/LIV.12996
P478
36 Suppl 1
P577
2016-01-01T00:00:00Z